This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.
Voluntarily participate and sign the informed consent form.
Age ≥ 18 years old, ≤ 75 years old, male or female.
Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
Expected survival ≥ 3 months.
Presence of any small cell carcinoma component in histopathology.
Subjects with other malignant tumors within 5 years prior to enrollment, and other tumors have been cured through local therapy, such as cured cutaneous squamous cell carcinoma, basal cell carcinoma, non-primary invasive bladder cancer, and prostate/cervical/breast cancer in situ.
Presence of brainstem, meningeal metastases, spinal cord metastases or compression, leptomeningeal metastases, or history of carcinomatous meningitis; Presence of active brain metastases.
During the screening period, imaging shows that the tumor invades, compresses, or occurs in the surrounding important organs (such as the heart and pericardium, trachea, esophagus, superior vena cava, etc.) or there is a risk of esophageal tracheal fistula or esophageal pleural fistula.
Parallel
JSKN016
DrugAdministered intravenously according to protocol.
Carboplatin
DrugAUC 5, Q3W, administered intravenously according to protocol.
Furmonertinib Mesylate
Drug160mg（cohort1A-b）or 80mg（cohort 5）, qd, administered according to protocol.
Ivonescimab
Drug20mg/kg, Q3W, administered intravenously according to protocol.
Docetaxel
Drug60mg/m\^2, Q3W, administered intravenously according to protocol.
Tislelizumab
Drug200mg, Q3W, administered intravenously according to protocol.
Pembrolizumab
Drug200mg, Q3W, administered intravenously according to protocol.
8
Treatment groupsSee each treatment group below.
ORR assessed by the investigator per RECIST v1.1
Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Safety reflected by AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
DOR assessed by the investigator per RECIST v1.1
Duration of response (DoR) assessed according to RECIST v1.1.
DCR assessed by the investigator per RECIST v1.1
Disease control rate (DCR) assessed according to RECIST v1.1.
TTR assessed by the investigator per RECIST v1.1
Time to response (TTR) is defined as the time to response base on RECIST v1.1.
PFS assessed by investigator per RECIST v1.1
Progression-free survival (PFS) is defined as the time from the date of initial administration till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first).
Click on the lead sponsor to view all of their trials.
